Sunesis Pharmaceuticals, Inc. (SNSS) Scheduled to Post Earnings on Thursday

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) is scheduled to be releasing its earnings data before the market opens on Thursday, July 27th. Analysts expect Sunesis Pharmaceuticals to post earnings of ($0.59) per share for the quarter.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.36. The firm had revenue of $0.67 million for the quarter, compared to analysts’ expectations of $1.57 million. During the same period in the prior year, the company earned ($0.12) EPS. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. On average, analysts expect Sunesis Pharmaceuticals to post $-2.02 EPS for the current fiscal year and $-1.60 EPS for the next fiscal year.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) opened at 2.56 on Thursday. The stock’s 50 day moving average price is $2.84 and its 200-day moving average price is $3.59. Sunesis Pharmaceuticals, Inc. has a 12 month low of $2.51 and a 12 month high of $6.30. The stock’s market cap is $54.94 million.

Several analysts recently commented on SNSS shares. Zacks Investment Research raised Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a report on Thursday, May 11th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $3.00 price objective on shares of Sunesis Pharmaceuticals in a report on Tuesday, May 2nd.

ILLEGAL ACTIVITY NOTICE: “Sunesis Pharmaceuticals, Inc. (SNSS) Scheduled to Post Earnings on Thursday” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Earnings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply